Merck’s MRK stock is up 5.6% in a month. The key reason for the increase was the strong second-quarter 2026 performance.

Merck (NYSE:MRK) said the FDA and EMA have accepted supplemental applications to expand ENFLONSIA for preventing RSV in young children at elevated risk. The filings seek to broaden ENFLONSIA's ...

In the most recent trading session, Merck (MRK) closed at $130.36, indicating a -1.11% shift from the previous trading day.

Merck (MRK) reported second-quarter results that topped Wall Street expectations, driven by continued strength in its ...

The latest lung cancer development represents a setback for one pathway rather than a verdict on the entire pipeline. Merck ...

Stock index futures were mixed on Thursday as investors looked ahead to another round of corporate earnings while monitoring developments in the Middle East ahead of weekly jobless claims data. Here ...

Merck (MRK) bid to expand the U.S. label for its RSV shot Enflonsia undergoes FDA review with a target action date of March ...

While the broader S&P Healthcare index has risen by 6% this year, and investors have generally favored healthcare stocks as a defensive strategy amid concerns over the economic impact of Trump’s ...

Merck (NYSE:MRK) stock has experienced a significant 22% decline this year, sharply underperforming the broader S&P 500 index, which is down only 1%. This downturn can be attributed to several factors ...

MRK is trading near the top of its 52-week range and above its 200-day simple moving average. Price change The price of MRK shares has increased $0.15 since the market last closed. This is a 0.12% ...